Kiora Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300395G8DB8ZFV365
    ISIN
    US49721T3095 (KPRX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    €74.55 16,614.7% undervalued
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€9.35M
    EBIT margin
    0.0%
    Net income
    -€10.29M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €643.83K +∞% -€12.89M +25.4%
    N/A -€23.01M +78.4%
    €19.56M -€6.46M -71.9%

    Dividends

    No dividend payouts

    Add to watchlist

    Notifications